Acta Scientific Cancer Biology (ASCB) (ISSN: 2582-4473)

Case Report Volume 7 Issue 2

Malignant Melanoma of AnoRectum

Seema Devi1*, Abhishek Kumar2 and P Minakshi3

1Additional Professor, Department of Radiation Oncology, IGIMS, Patna, India
2PG 3rd Year, Department of Radiation Oncology, IGIMS, Patna, India
3PG 1st Year, Department of Radiation Oncology, IGIMS, Patna, India

*Corresponding Author: Seema Devi, Additional Professor, Department of Radiation Oncology, IGIMS, Patna, India.

Received: March 24, 2023; Published: March 28, 2023


Melanoma develops from pigment containing cells. Melanocytes commonly occurs in skin. Commonly it occurs on the legs in females and on the back in the males [1]. Melanoma of anorectum is a rare disease constitutes only 0.5% to 4% of the all malignancies of anorectal malignancies with very poor prognosis, 10 to 19 months after surgical operations. A 32-year female presented with chief complaint of continuous rectal bleeding for last 1 year. Colonoscopy shown sessile growth extending from 8 to 12 O’clock with irregular surface 2cm from anal verge, seen up to caecum. All melanoma originates from derivative of neural crest, During foetal development melanocytes migrated in different sites of the body like skin, retina, uveal tract and mucosal surface [4,5]. 90% of melanoma are cutaneous melanoma. Many studies recommended systematic chemotherapy and radiation. Chemotherapy agents like cisplatin, vinblastine, dacarbazine. Interferon alpha and interleukin 2 are shown efficacy against melanoma [13] Ano Rectal melanoma is a rare disease and having poor prognosis. Patient may ignore the symptoms as having haemorrhoids, fistula due to symptoms like bleeding per rectum, pain during defecation. Biopsy should be followed by Immunohistochemistry examination for confirmation of diagnosis. Surgical approach, radiotherapy, chemotherapy can be considered depending on extent of the disease.

 Keywords: Anorectum; Melanoma; Melanocytes


  1. Slingluff CI Jr., et al. “Cutaneous melanoma”. In: DeVita VT Jr, Lawrence TS, Rosenberg SA, editors. Cancer: princi ples and practice of oncology. 9th Philadelphia (PA): Lippincott Williams and Wilkins (2011): 1643-1691.
  2. Brady MS., et al. “Anorectal melanoma. A 64-year experience at Memorial Sloan-Kettering Cancer Center”. Diseases of the Colon and Rectum 38 (1995): 146-151.
  3. Stefanou A and Nalamati SP. “Anorectal Melanoma”. Clinics in Colon and Rectal Surgery 24 (2011): 171-176.
  4. Singer M and Mutch MG. “Anal melanoma”. Clinics in Colon and Rectal Surgery 19 (2006): 78-87.
  5. Row D and Weiser MR. “Anorectal melanoma”. Clinics in Colon and Rectal Surgery 22 (2009): 120-126.
  6. Van Schaik PM., et al. “Melanoma of the rectum: A rare entity”. World Journal of Gastroenterology 14 (2008): 1633-1635.
  7. Slingluff CL Jr., et al. “Anorectal melanoma: Clinical characteristics and results of surgical management in twenty-four patients”. Surgery 107 (1990): 1-9.
  8. Kim KW., et al. “Primary malignant melanoma of the rectum: CT findings in eight patients”. Radiology 232 (2004): 181-186.
  9. Yeh JJ., et al. “The role of abdominoperineal resection as surgical therapy for ano-rectal melanoma”. Annals of Surgery 244 (2006): 1012-1027.
  10. Prichard RS., et al. “Positron emission tomography for staging and management of malignant melano-ma”. British Journal of Surgery 89 (2002): 389-396.
  11. Nilsson PJ and Ragnarsson-Olding BK. “Importance of clear resection margins in anorectal malignant melanoma”. British Journal of Surgery 97 (2010): 98-103.
  12. Ballo MI., et al. “Sphincter-sparing local excision and adjuvant radiation for anal-rectal melanoma”. Clinical Oncology 20 (2002): 4555-4558.
  13. Wilson MA and Schuchter LM. “Chemotherapy for melanoma”. Cancer Research and Treatment 167 (2016): 209-229.
  14. Chapman PB., et al. “Phase III multicenter randomized trial of the Dartmouth regimen versus dacarbazine in patients with metastatic melanoma”. Journal of Clinical Oncology 17 (1999): 2745-2751.


Citation: Seema Devi., et al. “Malignant Melanoma of AnoRectum" Acta Scientific Cancer Biology 7.2 (2023): 11-14.


Copyright: © 2023 Seema Devi., et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.


Acceptance rate35%
Acceptance to publication20-30 days
Impact Factor1.183

Indexed In

News and Events

  • Certification for Review
    Acta Scientific certifies the Editors/reviewers for their review done towards the assigned articles of the respective journals.
  • Submission Timeline for Upcoming Issue
    The last date for submission of articles for regular Issues is May 30, 2024.
  • Publication Certificate
    Authors will be issued a "Publication Certificate" as a mark of appreciation for publishing their work.
  • Best Article of the Issue
    The Editors will elect one Best Article after each issue release. The authors of this article will be provided with a certificate of "Best Article of the Issue"
  • Welcoming Article Submission
    Acta Scientific delightfully welcomes active researchers for submission of articles towards the upcoming issue of respective journals.

Contact US